Unicycive Therapeutics (UNCY) Retained Earnings (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Retained Earnings came in at -$140.6 million in Q1 2026, down 10.02% YoY from -$156.2 million in Q1 2025, and down 188.99% on a QoQ basis from $158.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) Retained Earnings (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Retained Earnings data on file, last reported at -$140.6 million in Q1 2026.
- Quarterly Retained Earnings fell 10.02% year-over-year to -$140.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.6 million (down 10.02% YoY) and the FY2025 annual result came in at $158.0 million, up 256.02% from the prior year.
- Retained Earnings eased to -$140.6 million in Q1 2026, from $158.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $158.0 million in Q4 2025 to a low of -$140.6 million in Q1 2026.
- A 5-year average of -$24.5 million and a median of -$56.7 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 513.31% — and 2024, when it sank 355.43%.
- Tracing UNCY's Retained Earnings over 5 years: stood at $33.5 million in 2022, then slumped by 292.45% to -$64.5 million in 2023, then plunged by 57.01% to -$101.3 million in 2024, then soared by 256.02% to $158.0 million in 2025, then sank by 188.99% to -$140.6 million in 2026.
- The last three Retained Earnings figures came in at -$140.6 million (Q1 2026), $158.0 million (Q4 2025), and -$113.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 195.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 195.64 Mn |
| Mar 31, 2026 | -140.60 Mn |
| Dec 31, 2025 | 158.00 Mn |
| Sep 30, 2025 | -113.20 Mn |
| Jun 30, 2025 | 123.45 Mn |
| Mar 31, 2025 | -127.80 Mn |
| Dec 31, 2024 | -101.27 Mn |
| Sep 30, 2024 | -79.70 Mn |
| Jun 30, 2024 | -75.65 Mn |
| Mar 31, 2024 | -85.50 Mn |
| Dec 31, 2023 | -64.50 Mn |
| Sep 30, 2023 | -56.74 Mn |
| Jun 30, 2023 | 33.02 Mn |
| Mar 31, 2023 | 33.48 Mn |
| Dec 31, 2022 | 33.52 Mn |
| Sep 30, 2022 | 33.28 Mn |
| Jun 30, 2022 | 33.01 Mn |
| Mar 31, 2022 | -19.48 Mn |
| Dec 31, 2021 | -15.94 Mn |
| Sep 30, 2021 | 32.17 Mn |